On November 12, 2024, Witte De, a Director at ResMed Inc (RMD, Financial), sold 796 shares of the company, according to the SEC Filing. Following this transaction, the insider now owns 6,723 shares of ResMed Inc.
ResMed Inc is a company that develops, manufactures, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders. These include sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.
Over the past year, the insider has sold a total of 1,516 shares and has not purchased any shares. This recent transaction is part of a broader trend observed within the company, where there have been 32 insider sells and no insider buys over the past year.
Shares of ResMed Inc were trading at $248.81 on the day of the transaction. The company has a market cap of approximately $34.13 billion. The price-earnings ratio of the stock is 30.79, which is slightly above the industry median of 29.995.
According to the GF Value, the intrinsic value of ResMed Inc is estimated at $268.40 per share, making the stock modestly undervalued with a price-to-GF-Value ratio of 0.93.
The GF Value is calculated based on historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor which considers past returns and growth, and future business performance estimates from Morningstar analysts.
This sale by the insider might be of interest to current and potential investors, providing insight into insider confidence and stock valuation perceptions at ResMed Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
